文献速递神经肿瘤

COVID-19大流行期间WHO III和IV级胶质瘤的神经肿瘤管理共识

Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas.
PubMed 文献 · Neuro Oncol · 2020-05-05

国际16位专家(神经肿瘤、神经外科、放疗及医学物理)制定共识,提出COVID-19大流行下高级别胶质瘤(HGG)的治疗策略。总体上神经肿瘤治疗不能显著延迟,启动治疗不应被COVID-19影响所抵消,并针对两个大流行场景(扩大期和危机期)给出分子亚组的详细跨学科治疗策略。

要点

  • HGG治疗不应因COVID-19显著延迟,启动治疗不应被疫情抵消。
  • 共识区分扩大期和危机期,按分子亚组制定跨学科治疗策略。
  • 建议基于16位国际专家共识,适用于大流行期间HGG管理。

核心结论

  • 该实践推荐为SARS-CoV-2大流行期间HGG患者提供务实框架和基于共识的缓解策略。

研究设计与样本

  • 共识声明由16位国际HGG治疗专家(神经肿瘤学家、神经外科医生、放疗肿瘤学家和医学物理师)制定。

主要发现

  • 神经肿瘤患者的治疗不能显著延迟,启动治疗不应被COVID-19所抵消。
  • 共识针对两个大流行场景(扩大期和危机期)和分子亚组提出详细跨学科治疗策略。

临床怎么用

  • 临床医生可依据该共识在COVID-19大流行期间平衡疫情风险与HGG肿瘤治疗,按扩大期或危机期及分子亚组选择策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Because of the increased risk in cancer patients of developing complications caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), physicians have to balance the competing risks of the negative impact of the pandemic and the primary tumor. In this consensus statement, an international group of experts present mitigation strategies and treatment guidance for patients suffering from high grade gliomas (HGG) during the coronavirus disease 2019 (COVID-19) pandemic. METHOD / RESULTS: 16 international experts in the treatment of HGG contributed to this consensus-based practice recommendation including neuro-oncologists, neurosurgeons, radiation -oncologists and a medical physicist. Generally, treatment of neuro-oncological patients cannot be significantly delayed and initiating therapy should not be outweighed by COVID-19. We present detailed interdisciplinary treatment strategies for molecular subgroups in two pandemic scenarios, a scale-up phase and a crisis phase. CONCLUSION: This practice recommendation presents a pragmatic framework and consensus-based mitigation strategies for the treatment of HGG patients during the SARS-CoV-2 pandemic.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Bernhardt D, Wick W, Weiss SE, et al. Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas. Neuro Oncol. 2020. PMID: 32369601. doi:10.1093/neuonc/noaa113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。